Mesoblast Ltd Net Assets
Mesoblast Ltd net assets. Based on the latest financial reports, Mesoblast Ltd (MESO) has net assets worth $568.40 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($773.08 Million) and total liabilities ($204.67 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset momentum of Mesoblast Ltd to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $568.40 Million |
| % of Total Assets | 73.52% |
| Annual Growth Rate | 17.49% |
| 5-Year Change | 14.36% |
| 10-Year Change | 9.99% |
| Growth Volatility | 268.05 |
Net Assets of Mesoblast Ltd (2005–2026)
Net assets of Mesoblast Ltd from 2005 to 2026. This chart illustrates how Mesoblast Ltd's net assets have evolved over time, based on quarterly financial data. See MESO net asset quality score to measure how much of total assets are equity-financed.
Annual Net Assets for Mesoblast Ltd (2005–2026)
The table below shows the annual net assets of Mesoblast Ltd from 2005 to 2026. For live market cap and overall valuation, see Mesoblast Ltd (MESO) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2026-06-30 | $568.40 Million | -4.86% |
| 2025-06-30 | $597.44 Million | +24.38% |
| 2024-06-30 | $480.36 Million | -4.28% |
| 2023-06-30 | $501.84 Million | +0.96% |
| 2022-06-30 | $497.04 Million | -14.51% |
| 2021-06-30 | $581.40 Million | +5.84% |
| 2020-06-30 | $549.33 Million | +14.19% |
| 2019-06-30 | $481.05 Million | -11.90% |
| 2018-06-30 | $546.01 Million | +5.66% |
| 2017-06-30 | $516.77 Million | -2.16% |
| 2016-06-30 | $528.16 Million | -13.33% |
| 2015-06-30 | $609.36 Million | +6.58% |
| 2014-06-30 | $571.72 Million | -9.29% |
| 2013-06-30 | $630.27 Million | +31.62% |
| 2012-06-30 | $478.85 Million | -7.17% |
| 2011-06-30 | $515.84 Million | +1260.38% |
| 2010-06-30 | $37.92 Million | +47.03% |
| 2009-06-30 | $25.79 Million | -1.63% |
| 2008-06-30 | $26.22 Million | +27.64% |
| 2007-06-30 | $20.54 Million | +71.66% |
| 2006-06-30 | $11.97 Million | -37.89% |
| 2005-06-30 | $19.26 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Mesoblast Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 106693263100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Mesoblast Ltd Net Assets Breakdown (June 2026)
Mesoblast Ltd net assets breakdown by equity component as of June 2026.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.53 Billion | 269.31% |
| Other Comprehensive Income | $106.03 Million | 18.65% |
| Total Equity | $568.40 Million | 100.00% |
Mesoblast Ltd Competitors by Market Cap
The table below lists competitors of Mesoblast Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Grupo Profuturo S.A.B. de C.V
MX:GPROFUT
|
$1.97 Billion |
|
Dermapharm Holding SE
XETRA:DMP
|
$1.97 Billion |
|
Transportadora de Gas del Sur SA B
BA:TGSU2
|
$1.97 Billion |
|
CleanSpark Inc
NASDAQ:CLSK
|
$1.97 Billion |
|
Sarepta Therapeutics Inc
NASDAQ:SRPT
|
$1.97 Billion |
|
Zhejiang Weixing New Building Materials Co Ltd
SHE:002372
|
$1.97 Billion |
|
Snowline Gold Corp.
V:SGD
|
$1.96 Billion |
|
HCI Group Inc
NYSE:HCI
|
$1.96 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Mesoblast Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from 597,442,000 to 568,405,000, a change of -29,037,000 (-4.9%).
- Net loss of 57,756,862 reduced equity.
- New share issuances of 2,602,000 increased equity.
- Other comprehensive income increased equity by 6,535,000.
- Other factors increased equity by 19,582,862.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-57.76 Million | -10.16% |
| Share Issuances | $2.60 Million | +0.46% |
| Other Comprehensive Income | $6.54 Million | +1.15% |
| Other Changes | $19.58 Million | +3.45% |
| Total Change | $- | -4.86% |
Book Value vs Market Value Analysis
This analysis compares Mesoblast Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.45x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 42.31x to 3.45x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-06-30 | $0.36 | $15.16 | x |
| 2006-06-30 | $0.22 | $15.16 | x |
| 2007-06-30 | $0.38 | $15.16 | x |
| 2008-06-30 | $0.49 | $15.16 | x |
| 2009-06-30 | $0.48 | $15.16 | x |
| 2010-06-30 | $0.71 | $15.16 | x |
| 2011-06-30 | $9.59 | $15.16 | x |
| 2012-06-30 | $8.91 | $15.16 | x |
| 2013-06-30 | $11.72 | $15.16 | x |
| 2014-06-30 | $10.63 | $15.16 | x |
| 2015-06-30 | $11.33 | $15.16 | x |
| 2016-06-30 | $9.82 | $15.16 | x |
| 2017-06-30 | $9.61 | $15.16 | x |
| 2018-06-30 | $5.86 | $15.16 | x |
| 2019-06-30 | $9.73 | $15.16 | x |
| 2020-06-30 | $10.39 | $15.16 | x |
| 2021-06-30 | $9.61 | $15.16 | x |
| 2022-06-30 | $7.28 | $15.16 | x |
| 2023-06-30 | $5.98 | $15.16 | x |
| 2024-06-30 | $4.87 | $15.16 | x |
| 2025-06-30 | $4.95 | $15.16 | x |
| 2026-06-30 | $4.39 | $15.16 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Mesoblast Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -10.16%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -47.82%
- • Asset Turnover: 0.16x
- • Equity Multiplier: 1.36x
- Recent ROE (-10.16%) is above the historical average (-19.89%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | -7.63% | -292.39% | 0.02x | 1.11x | $-3.40 Million |
| 2006 | -69.36% | -294.09% | 0.17x | 1.37x | $-9.50 Million |
| 2007 | -42.49% | -519.74% | 0.08x | 1.03x | $-10.78 Million |
| 2008 | -38.38% | -1105.99% | 0.03x | 1.06x | $-12.68 Million |
| 2009 | -47.64% | -1379.29% | 0.03x | 1.05x | $-14.86 Million |
| 2010 | -38.98% | -268743.55% | 0.00x | 1.04x | $-18.57 Million |
| 2011 | 17.56% | 74.93% | 0.16x | 1.48x | $39.02 Million |
| 2012 | -14.86% | -185.86% | 0.05x | 1.50x | $-119.03 Million |
| 2013 | -9.78% | -214.21% | 0.03x | 1.40x | $-124.69 Million |
| 2014 | -14.16% | -311.62% | 0.03x | 1.57x | $-138.13 Million |
| 2015 | -19.59% | -502.64% | 0.02x | 1.67x | $-180.30 Million |
| 2016 | -0.78% | -9.70% | 0.06x | 1.30x | $-56.94 Million |
| 2017 | -14.86% | -3184.70% | 0.00x | 1.27x | $-128.49 Million |
| 2018 | -6.46% | -203.51% | 0.03x | 1.27x | $-89.89 Million |
| 2019 | -18.67% | -537.01% | 0.03x | 1.36x | $-137.90 Million |
| 2020 | -14.19% | -242.38% | 0.04x | 1.34x | $-132.87 Million |
| 2021 | -17.00% | -1325.25% | 0.01x | 1.28x | $-156.95 Million |
| 2022 | -18.38% | -894.59% | 0.02x | 1.33x | $-141.05 Million |
| 2023 | -16.32% | -1091.71% | 0.01x | 1.33x | $-132.07 Million |
| 2024 | -18.31% | -1490.27% | 0.01x | 1.39x | $-135.99 Million |
| 2025 | -17.10% | -593.92% | 0.02x | 1.31x | $-161.89 Million |
| 2026 | -10.16% | -47.82% | 0.16x | 1.36x | $-114.60 Million |
Industry Comparison
This section compares Mesoblast Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $126,960,080
- Average return on equity (ROE) among peers: -97.16%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Mesoblast Ltd (MESO) | $568.40 Million | -7.63% | 0.36x | $1.97 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $29.61 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $4.06 Million | -282.32% | 0.21x | $248.75 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $15.18 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $189.45 Million | -60.80% | 0.14x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $59.19 Million | -23.76% | 0.21x | $834.03 Million |
| ABVC Biopharma Inc (ABVC) | $13.30 Million | -59.47% | 0.58x | $26.65 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $7.56 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $17.86 Million | -80.65% | 0.23x | $3.55 Billion |
About Mesoblast Ltd
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers remestemcel-L-rknd, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid … Read more